ASCO 2021 | Head and neck cancer highlights at ASCO 2021

Ari Rosenberg, MD, University of Chicago Medicine, Chicago, IL, discusses the highlights concerning head and neck cancer from the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting. Treatment with gemcitabine, cisplatin, and anti-PD-1 therapy produced promising results for the use of primary anti-PD-1 and chemotherapy to treat nasopharynx cancer. In addition, a significant pathologic response was found in resectable oral cavity cancer patients when subject to neoadjuvant immunotherapy, potentiating the use of adjuvant therapy in oral cavity cancer treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.